Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,401–1,500 of 3,704
Long-Term Results at 10 Years of Pouch Resizing for Roux-en-Y Gastric Bypass Failure
Drai, C., Chierici, A. P., Schiavo, L., Mazahreh, T. S., Schneck, A.-S., & Iannelli, A. (2022) · Nutrients · doi:10.3390/nu14194035 · Cited by 8
“The recent results obtained with the incretins analogues in individuals with a BMI at 27 and at least one obesity-related complication and those with a BMI > 30 are of great interest and may revolutionize the field of bariatric surgery in the foreseeable future [31].”
BackgroundKishimoto, I. (2023) · Metabolites · doi:10.3390/metabo13060754 · Cited by 8
“Tirzepatide, a once-weekly subcutaneous injectable peptide with agonist activity at both the GIP and GLP-1 receptors [61], provided substantial and sustained reductions in body weight [62].”
BackgroundNguyen, T. K., Wong, E., & Cope, R. J. (2023) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001643 · Cited by 8
Marshall, L. Z., Gleason, P. P., Friedlander, N., Farley, J., & Urick, B. Y. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.3.281 · Cited by 6
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“Improvements were also reported in systolic blood pressure, triglycerides, non-high-density lipoprotein (HDL) cholesterol, HDL, and fasting insulin [109].”
The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Guo, Y., Chu, L., Cai, X., Wu, H., Yan, J., Li, Z., Jiao, R., Bai, S., Yang, W., Lv, F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110867 · Cited by 6
Decoding Obesity Management Medications and the Journey to Informed Treatment Choices for Patients
Koball, A. M., Ames, G. E., Grothe, K. B., Clark, M. M., Collazo–Clavell, M. L., & Elli, E. F. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.10.003 · Cited by 6
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf004 · Cited by 9
Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?
Lah, S., & HOCKING, S. L. (2025) · Internal Medicine Journal · doi:10.1111/imj.16625 · Cited by 8
“11,12 The SELECT cardiovascular outcomes trial was the fi rst to demonstrate a signi fi cant reduction in major adverse cardiovascular events in a population with obesity and established cardiovascular disease but without T2D with the composite outcome of cardiovascular death, non-fatal myocardial…”
Trending Modalities in Type 2 Diabetes Prevention
Lundgrin, E. L., & Hatipoğlu, B. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf040 · Cited by 8
Heymsfield, S. B., Ramirez, S., Yang, S., Thomas, D. M., Brown, J. C., Compton, S. L. E., Schuna, J. M., Smith, S. R., Ludwig, D. S., & Ebbeling, C. B. (2025) · Obesity · doi:10.1002/oby.24255 · Cited by 6
“Another factor making interpretation of GLP1-RA studies difficult is the pooling of body composition results for male and female individuals [4, 7, 8].”
Himmerich, H. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01813-x · Cited by 9
“Während die herkömmlichen GLP-1-Rezeptoragonisten zu einem Gewichtsver-lust von ca. 15% führen, erreicht Tirzepa-tid bei einer wöchentlich injizierten Dosis von 10mg oder 20mg einen Gewichtsver-lust von ~20% [4].”
Rhabdomyolysis associated with the use of tirzepatide
Sonavane, K., Shirsat, P. D., Agrawal, G., & Agarwal, B. (2025) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2025_005392 · Cited by 6
“Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has gained a wide popularity in recent years for weight loss in adult patients with obesity with or without type 2 diabetes [1,2] .”
Unravelling the GIPR agonist versus antagonist paradox
Adriaenssens, A. E. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01299-6 · Cited by 7
Kasagga, A., Assefa, A. K., Amin, M. N., Hashish, R., Tabari, K. A., Swami, S. S., & Nakasagga, K. (2025) · Cureus · doi:10.7759/cureus.85531 · Cited by 16
“The findings of this meta-analysis align with and build upon results from individual SURMOUNT trials, which have demonstrated that tirzepatide induces significant weight loss in both diabetic and non-diabetic populations [7-10].”
InfluentialLamb, I. M., White, A. D., Willard, F. S., Chalmers, M. J., & Xiao, J. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00079 · Cited by 7
“Additionally, the dual agonist tirzepatide (targeting GLP-1R and GIPR) was recently approved for the treatment of obesity 11 and type 2 diabetes 8 .”
Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss
Heald, A. H., Reynolds, G. P., Nash, I., Boyle, O., Daly, C., Longson, D., O'Shea, D. B., Ingram, J., Holt, R. I. G., Firth, J., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03261-0 · Cited by 9
“It therefore seems likely that GLP-1 receptor agonists and other incretin therapies could be of substantial value in addressing the challenge of obesity in people with SMI, given the well-established evidence for their ability to reduce weight in individuals who are overweight [12, 13].”
InfluentialLizcano, F., Sanabria, D., & Aviles, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1622186 · Cited by 9
“…with glucose-dependent insulinotropic polypeptide (GIP)-are rapidly gaining traction, and it is expected that new formulations will continue to emerge, incorporating peptides capable of modulating metabolism and thermogenesis (Jastreboff et al., 2022; Rosenstock et al., 2023; Loomba et al., 2024).”
Chigutsa, E., Her, L., Ma, X., Urva, S., & Schneck, K. B. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3750 · Cited by 11
Carey, I. M., Harris, T. J., Chaudhry, U. A. R., DeWilde, S., Limb, E. S., Bowen, L., Audi, S., Cook, D. G., Whincup, P. H., Sattar, N. A., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01828-z · Cited by 8
“Given the high global prevalence of both T2D and obesity [15], with the recent emergence of novel weight loss therapies [16, 17], a better understanding of the interaction between BMI, diabetes and infection would be desirable and informative for patients, clinicians and policy-makers.”
Bujdei-Tebeică, I., Mihai, D. A., Stoian, A. P., Ștefan, S., Stoicescu, C. I., & Serafinceanu, C. (2025) · Medicina · doi:10.3390/medicina61081399 · Cited by 11
“In the SURMOUNT-1 substudy, fat mass loss was indeed approximately threefold greater than lean mass loss [63].”
Lee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 11
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
Lopez, R. F. R., Barrera, D. L., Muñoz, M. C. A., & Díaz, M. (2025) · Cureus · doi:10.7759/cureus.90021 · Cited by 17
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 9
Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis
Gras, C., Wit, V. D., Oussedik, N., et al. (2025) · European Journal of Clinical Nutrition · doi:10.1038/s41430-025-01653-7 · Cited by 6
Obesity and Metabolic Syndrome: Current Insights and Future Directions
Zarkasi, Z., Mudaliar, R. N., Majeed, W., & Syed, A. A. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2025.0127 · Cited by 12
Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy
Ma, J., Mao, L., Yang, L., Xie, Q., Fan, R., Lu, X., Huang, X., Tong, N., & Duan, Z. (2025) · MedComm · doi:10.1002/mco2.70359 · Cited by 20
“Particularly noteworthy is tirzepatide, a novel dual GLP-1/GIP receptor agonist that has shown superior efficacy in glycemic control and weight reduction [231–233].”
Luc, G., Dedieu, A., Canard, G., Cesard, A., Brunet, A., Furois, C., Leterrier, A., Daridon, B., Mendes, L., Brighen, E., et al. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08258-w · Cited by 6
“However, the efficacy observed in our real-life cohort (percentage of total body weight loss = 5.38% in the GLP-1 group) remained lower than that reported in randomized controlled trials [3, 11].”
InfluentialPark, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
“Semaglutide 2.4 mg (Wegovy ® ) and tirzepatide (Zepbound ® ), approved for the treatment of obesity in 2021 and 2024, respectively, produced corresponding mean weight loss of 17% and 23% in clinical trials of subjects with obesity, but without T2D (16, 17).”
InfluentialIsmail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 7
Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022–2025)
Almansour, H. A., Thaibah, H. A., Alfarhan, M., Al-Qahtani, S. A., Khardali, A., & Alshammari, T. M. (2025) · Healthcare · doi:10.3390/healthcare13182259 · Cited by 18
“These symptoms, although often transient, may lead to discontinuation of treatment or dose interruption [36].”
Obesity Medication Treatment Perspectives Among People with Overweight or Obesity
Ostrominski, J. W., Chhibber, A., Kuti, E. L., Clark, B. J., & Donato, B. M. K. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s555622 · Cited by 8
Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 10
The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea
Mifsud, C. S., Kolla, B. P., Rushlow, D. R., & Mansukhani, M. P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2574848 · Cited by 8
“…mentioned, the SURMOUNT-1 trial showed improvement in multiple cardiovascular and metabolic risk factors, including waist circumference, systolic and diastolic BP, and fasting insulin, lipid, and aspartate aminotransferase levels compared to placebo in patients treated with tirzepa-tide [34].”
InfluentialThe Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Weber, L., Sharbabaki, M. H., Fuchs, B., Alberton, P., Giunta, R. E., Mert, S., & Thierfelder, N. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-11002-7 · Cited by 9
“GLP-1-RA such as liraglutide [ 4], semaglutide [ 5 ], and the dual agonist tirzepatide [ 6 ], activating both the GLP1-and the gastric-inhibitory polypeptide receptor (GIP-R), have been shown to significantly reduce body weight, mak - ing them a promising therapeutic option for the treatment of…”
GOETZ, I. A., Kanu, C., Hoover, A., Jimenez‐Moreno, C., Karn, H., Kimel, M., Neff, L. M., & Boye, K. S. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100220 · Cited by 9
“…trial, weekly treatment with tirzepatide (15 mg), a glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist, led to a 20.9 % mean weight reduction at week 72 in adults with obesity or overweight (with ≥ 1 obesity-related complication excluding diabetes) [10].”
InfluentialTirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 23
Sattar, N. A., Scilletta, S., Stefański, A., Wang, H., Daly, J. W., & Linetzky, B. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.10.009 · Cited by 9
Self-citationAssociation of tirzepatide and the risk of suicide in a real-world cohort
Yu, W.-S., Huang, J., Lo, S., Huang, C., Yang, Y., & Kornelius, E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1626103 · Cited by 10
“Recently, tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated considerable ef fi cacy in improving glycemic control and promoting weight reduction in patients with obesity (7 – 9).”
Decoding the hallmarks of GLP-1RA weight-loss super-responders
Venkatakrishnan, A., Murugadoss, K., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag021 · Cited by 8
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring
Aktürk, H. K., Perkins, B. A., & Dunn, T. C. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390818 · Cited by 8
“…RAs, 17,18 and fi rst-in-class medications, such as tirzepatide, a dual GLP1, and glucose-dependent insulino-tropic polypeptide receptor agonist, 19 – 22 and fi nerenone, a nonsteroidal mineralocorticoid receptor antagonist that offers substantial renal and cardiovascular bene fi ts for…”
Trocchio, L., & Peters, F. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100237 · Cited by 9
McMath, A. L., & Gallagher, D. (2025) · Obesity Reviews · doi:10.1111/obr.70041 · Cited by 8
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 10
Chakravarthy, M. V., Rodríguez, R., Hergarden, A. C., Elliott, M. A., Frías, J. P., ARGÜELLES-TELLO, F. A., Tenorio, E., Rankin, J. E., Wu, J., Krishnan, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102291 · Cited by 8
“More recently, treatment with the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, tirzepa-tide, resulted in substantial weight loss and improved glycemic control among participants with obesity with or without T2D [6,8,10,11].”
Brown, A., Patel, S., Li, E., Vu, A. H., Somoza, E., Chen, J., Zhang, D. “., Massie, A. B., Orandi, B. J., Segev, D. L., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12403-y · Cited by 10
Caturano, A., Nilo, D., Lorenzo, G. D., Rocco, M. P., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Moretto, S. M., Acierno, C., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43143 · Cited by 9
“Furthermore, in the SURMOUNT-1 trial, tirzepatide led to substantial weight loss (up to –21% of baseline body weight) and improvements in hepatic steatosis assessed by MRI-PDFF [171].”
Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide
Rzepiński, Ł., Tywoniuk, A., Jaraczewska, J., Al-Shaer, A., & Wiciński, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412028 · Cited by 8
“…weeks, 15% weight loss was achieved in individuals receiving 5 mg of tirzepatide, 19.5% in those who received tirzepatide at a dose of 10 mg, and 20.9% in those receiving 15 mg of tirzepatide, and 3.1% weight loss was observed in the placebo group ( p 0.001 for all comparisons with placebo) [78].”
InfluentialChanges in Eating Behaviour During Treatment With Obesity Medications
Chong, M. C., Ko, T. Y. L., le Roux, P. L., & le Roux, C. W. (2025) · Clinical Obesity · doi:10.1111/cob.70065 · Cited by 9
Jalan, A., Murzinski, E. S., Jansen, P. J., Miller, R. D., Embry, M. C., Scherer, R. B., Moomaw, J. F., Williams, K. M., Fisher, C. A., James, J., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202520060 · Cited by 7
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
“Tirzepatide, a dual agonist for the GLP-1/GIP receptors, was developed by Eli Lilly with a similar half-life as semaglutide and 21 % weight loss in patients with obesity [38,39].”
The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF
Komić, L., Komic, J., Pavlović, N., Kumrić, M., Bukić, J., Tomić, I. J., & Božić, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020612 · Cited by 11
“Dual-incretin agonists such as tirzepatide exemplify the benefits of coordinated metabolic modulation: activation of both GIP and GLP-1 receptors produces superior improvements in weight, glycemic control, and inflammatory tone compared with GLP-1 receptor agonism alone [170,171].”
Jansson, A. K., Gómez‐Martín, M., Hedin, L. E., Clarke, E. D., Cross, V., Stanford, J., Taylor, R., Bogl, L. H., de Vlieger, N., Koochek, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70077 · Cited by 13
Gao, Y., Pang, X., Zhang, H., Li, D., Han, J., Chen, Z., Chen, X., & Li, D. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2025.1736472 · Cited by 10
“…excretion by approximately 24%, slowed the annual decline in estimated glomerular filtration rate (eGFR) by 0.3–0.9 mL/min/1.73 m 2 , and provided greater benefits in patients with baseline eGFR values below 60 mL/min/1.73 m 2 (Shaman et al., 2022; Jastreboff et al., 2022; Pratley et al., 2024).”
InfluentialThe evolving landscape of pharmacogenomics: Current achievements and future directions
Lauschke, V. M., & Ingelman‐Sundberg, M. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100122 · Cited by 16
“138,139 Notably, both GIP receptor (GIPR) agonists and antagonists appear to enhance weight loss, 140 — 142 raising questions about whether GIP stimulation or inhibition is more beneficial.”
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity
Roth, C. L., Doelman-Oldenburger, N. J., & van Santen, H. M. (2026) · Drugs · doi:10.1007/s40265-025-02280-z · Cited by 7
Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities
Evans, P. C., Vilahur, G., Kleinbongard, P., Osto, E., Remme, C. A., Madonna, R., Aksentijević, D., Sourij, H., Davidson, S. M., Santovito, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag116 · Cited by 10
Seminara, G., Leuzzi, M., MEDURI, L., GRECO, E. A., & Aversa, A. (2026) · Minerva Endocrinology · doi:10.23736/s2724-6507.26.04541-0 · Cited by 7
Yamauchi, T., Becker, N., Hagemann, C. A., Huang, K.-C., Kiyosue, A., Lim, S., Onishi, Y., Kosuvaripalli, A., Takano, T., & Ishigaki, Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00402-4 · Cited by 12
Self-citationGupta, A. K., Teasell, E. M., Economopoulos, V., & Mirmirani, P. (2026) · Science Progress · doi:10.1177/00368504261444578 · Cited by 12
“2,37 With lower rates of weight loss associated with TE in women than men, indicating they may be more vulnerable to TE even with a lower rate of weight loss.”
βHB inhibits glucose-induced GLP-1 secretion in GLUTag and human jejunal enteroids
Elebring, E., Casselbrant, A., Persson, S. M. T., Fändriks, L., & Wallenius, V. (2023) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0115 · Cited by 8
Current Treatment Options, Including Diet, Exercise, and Medications
Noureddin, M., & Abdelmalek, M. F. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.008 · Cited by 7
Blockbuster Medications for Obesity: A Primer for Nephrologists
Zeitler, E. M., Dabb, K., Nadeem, D., Still, C. D., & Chang, A. R. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.009 · Cited by 6
Is obesity the next step in evolution through brain changes?
Ricart, W., Crujeiras, A. B., Mateos, A., Castells-Nobau, A., & Fernández‐Real, J. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103927 · Cited by 8
“Novel therapeutic targets have been identified, with some drugs achieving weight reduction of 15% – 17.4% in year-long treatments (Wilding et al., 2021; Rubino et al., 2021; Jastreboff et al., 2022).”
InfluentialPublic health perspective on new weight loss medications
Mytton, O. T., Head, V., & Reckless, I. P. (2024) · BMJ · doi:10.1136/bmj.q196 · Cited by 8
Talay, L., & Vickers, M. (2024) · Journal of Community Medicine & Public Health · doi:10.29011/2577-2228.100422 · Cited by 6
“In recent years, randomized controlled trials have demonstrated the unprecedented effectiveness of Glucose-like peptide-1 receptor agonists (GLP-1 RAs) in inducing weight loss for people with overweight and obesity [2-4].”
BackgroundThe Role of Obesity and Inflammation in Breast Cancer Recurrence
Chew, S. M., Liu, B., Shen, S., & Iyengar, N. M. (2024) · Current Breast Cancer Reports · doi:10.1007/s12609-024-00550-5 · Cited by 8
“The mean weight reduction with use of these agents is 8–15% of baseline body weight, with 63–86% of patients achieving ≥ 5% reduction in body weight and 33–69% achieving ≥ 10% [82–84].”
Self-citationElfers, C., Chichura, K. S., Ashlaw, E. F., Chepurny, O. G., Holz, G. G., Doyle, R. P., & Roth, C. L. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.035 · Cited by 8
The Complex Connection between Obesity and Cancer: Signaling Pathways and Therapeutic Implications
El‐Tanani, M., Rabbani, S. A., Aljabali, A. A. A., Matalka, I. I., El‐Tanani, Y., Rizzo, M., & Tambuwala, M. M. (2024) · Nutrition and Cancer · doi:10.1080/01635581.2024.2361964 · Cited by 9
“It is classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (143).”
Harrington, J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10410-0 · Cited by 6
Challenges in the care and treatment of patients with extreme obesity
Stumpf, M. A. M., & Mancini, M. C. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0335 · Cited by 11
“%) in people with obesity (8).”
Blevins, J. E., Honeycutt, M. K., Slattery, J. D., Goldberg, M., Rambousek, J. R., Tsui, E. W., Dodson, A. D., Shelton, K. A., Salemeh, T. S., Elfers, C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1432928 · Cited by 6
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
“Treatment discontinuation due to adverse events was noted in 4.3% of the 5-mg group, 7.1% of the 10-mg group, 6.2% of the 15-mg group, and 2.6% of the placebo group [108].”
InfluentialDifferential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes
Losada-Díaz, F., Lizarazo-Bocanegra, S., Perdomo-Lugo, J. J., Gutiérrez-Romero, S. A., Correa-Osio, I., & Mendivil, C. O. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01646-y · Cited by 11
“The pivotal study of tirzepatide in patients with overweight or obesity but not diabetes (SURMOUNT‑1), found a 20.9% (22 kg) weight reduction at 72 weeks with the 15 mg/ week dose [37].”
BackgroundInfluentialBariatric and Metabolic Surgery in the Adult Population
Sharew, B., Kodur, N., Corcelles, R., & Mauer, Y. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.05.022 · Cited by 7
Camilleri, M. (2024) · The Journal of Physiology · doi:10.1113/jp287535 · Cited by 7
“Weekly administered GLP-1RA semaglutide and dual incretin (GLP-1 and GIP) agonist, tirzepatide, are significant advances among anti-obesity medications based on efficacy [reaching ∼ 15% or 20% mean weight loss at 68 or 72 weeks (e.g. Jastreboff et al., 2022; Wadden et al., 2021)].”
Arora, P., & Ramagopalan, S. V. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0212 · Cited by 6
Glucagon‐like peptide‐1 receptor agonists and upper endoscopy: a real‐world experience
Jirapinyo, P., Siranart, N., & Thompson, C. C. (2025) · Obesity · doi:10.1002/oby.24190 · Cited by 9
Clark, J. M., Smith, B. J., Juusola, J. L., & Kumar, R. B. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70036 · Cited by 8
Brachs, S., Soll, D., Beer, F., Huckauf, N., Konkar, A. A., Spranger, J., Rütten, H., & Mai, K. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae151 · Cited by 7
Medical Management of Obesity: Current Trends and Future Perspectives
Calderón, A., Aguilera-Astudillo, M., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1503 · Cited by 8
Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?
Al-Awadi, A. A., Gray, S. R., & Al‐Ozairi, E. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09947-8 · Cited by 12
“This is similar to data from the SURMOUNT-1 trials where in people with obesity, but not diabetes, Tirzepatide treatment resulted in a 26% greater fat mass loss and 8% greater lean mass loss compared to placebo [124].”
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Ard, J. D., Kaplan, L. M., Kahan, S. I., Kumar, R. B., Kan, H., Dunn, J. P., Sims, T. J., Ahmad, N. N., King-Concialdi, K., Drakeley, S. C., et al. (2025) · Population Health Management · doi:10.1089/pop.2024.0239 · Cited by 10
“Furthermore, data on short-term bene fi ts of AOMs such as weight reduction and improvement in cardiometabolic risk factors as well as long-term bene fi ts 36,37 can equip the ER to make informed decisions.”
Self-citationTanashat, M., Al‐Ajlouni, Y. A., Abuelazm, M., Altobaishat, O., Manasrah, A., Turkmani, M. M., Khan, U., & Abouzid, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00726-z · Cited by 9
“The sensitivity analysis excluding Jastreboff et al. [31] resulted in reduced heterogeneity ( I 2 = 93%; p < 0.0001), and the overall results became nonsignificant (MD − 0.23 %; 95% CI − 0.54 to 0.08; p = 0.14).”
InfluentialEvans, M., Evans, W., Godbeer, F., Edgar, L., Spaepen, E., & Davies, A. L. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03194-8 · Cited by 11
“Full patient demographic details have been previously published [22].”
InfluentialNavigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure
Wang, W. T., Green, D. B., Ibrahim, R., Abdelnabi, M. H., Pham, H. N., Forst, B. J., Allam, M., Sarkis, P., Bcharah, G., Farina, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051108 · Cited by 9
“The SURMOUNT-1 trial, a similar randomized control trial with 2359 nondiabetic patients with increased BMI, showed that tirzepatide, a dual GLP-1 and GIP receptor agonist, administered weekly for 72 weeks, resulted in a 33.9% reduction in FM and a 10.9% reduction in LM [9].”
InfluentialTirzepatide to treat obesity: phase III results
Hindson, J. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00657-z · Cited by 6
Tirzepatide decreases systolic and diastolic blood pressure
Çöpür, S., Demiray, A., Cherney, D. Z. I., Tuttle, K. R., & Kanbay, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.04.005 · Cited by 8
Cancer cachexia as a blueprint for treating obesity
Jaschke, N., & Rachner, T. D. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.04.001 · Cited by 6
Edens, M. A., van Dijk, P. R., Hak, E., & Bilo, H. J. G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110719 · Cited by 8
Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
Müller, T. D., & Blüher, M. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01530-0 · Cited by 11
Metabolic and Bariatric Endoscopy: A Mini-Review
Norton, B. C., Telese, A., Papaefthymiou, A., Aslam, N., Makaronidis, J., Murray, C. D., & Haidry, R. J. (2023) · Life · doi:10.3390/life13091905 · Cited by 7
“New pharmacological agents including GLP-1 agonists and combined GLP-1/gastro-intestinal peptide agonists have been shown to be highly effective obesity treatments [52,53].”
BackgroundGlycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes
Vázquez, L. A., Romera, I., Santos, M. R., & Escalada, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01467-5 · Cited by 9
“New therapies, such as tirzepatide, have demonstrated very high effi-cacy for weight reduction [7].”
BackgroundBrix, J. M., Andersen, B. L., Aydınkoç-Tuzcu, K., Beckerhinn, P., Brossard-Eitzinger, A., Cavini, A. M., Ciardi, C., Clodi, M., Eichner, M., Erlacher, B., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02270-9 · Cited by 17
(2023) · Nature Medicine · doi:10.1038/s41591-023-02614-y · Cited by 7
Avgerinos, I., Kakotrichi, P., Karagiannis, T., Bekiari, E., & Τσάπας, Α. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2324918 · Cited by 7
“The most common adverse events were mild-to-moderate transient gastrointestinal events [55].”
BackgroundHeightened Vigilance Needed When Patients Are Prescribed GLP-1 and GIP Agonists
Johnson, T. A., Incze, M. A., & Silverstein, W. K. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.3732 · Cited by 7
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.